← Back to Search

Other

ALTO-300 for Depression

Phase 2
Waitlist Available
Research Sponsored by Alto Neuroscience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured 6 times over 8 weeks
Awards & highlights

Study Summary

This trial will help to identify how well the drug ALTO-300 works in people, as well as what effects it has on the body.

Eligible Conditions
  • Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured 6 times over 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured 6 times over 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-300
Number of Participants With Clinically Significant Vital Signs Abnormalities as a Measure of Safety and Tolerability of ALTO-300
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-300
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ALTO-300Experimental Treatment1 Intervention
ALTO-300 tablet PO; daily dosing 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALTO-300 PO Tablet
2022
Completed Phase 2
~150

Find a Location

Who is running the clinical trial?

Alto NeuroscienceLead Sponsor
7 Previous Clinical Trials
823 Total Patients Enrolled
7 Trials studying Depression
823 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the study population extend to individuals aged sixty and older?

"This clinical trial has a lower age limit of 18, and an upper bound of 74 for those that wish to take part."

Answered by AI

What is the upper limit of individuals participating in this clinical endeavor?

"Correct. Per the information provided on clinicaltrials.gov, this medical study is actively seeking participants since its initial posting in February 2022 with a recent update on October 19th of the same year. The researchers are aiming to recruit 200 patients from 4 different sites."

Answered by AI

How hazardous is ALTO-300 for individuals using it therapeutically?

"ALTO-300 has been deemed safe based on prior clinical data, so we assigned it a score of 2. As this is only in the second stage of trials, there is yet to be evidence confirming its efficacy."

Answered by AI

How many healthcare facilities are facilitating this investigation?

"At the moment, 4 medical sites are currently administering this trial. Those situated in near Atlanta, New york and Dallas as well as other spots should pick their closest centre to minimize travelling needs if they take part."

Answered by AI

Is the research team recruiting participants at this point in time?

"According to the clinicaltrials.gov portal, this medical trial was publicly published on February 3rd 2022 and has most recently been modified on October 19th 2022. It is currently enrolling suitable candidates."

Answered by AI

Who is eligible to join this research study?

"This clinical trial is accepting 200 individuals suffering from depression, ranging in age from 18 to 74. Crucially, participants must adhere to all study assessments and procedures and cannot be expecting or lactating during the duration of this investigation."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
Other
New York
Texas
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
Cerebral - New York City
Cerebral - Dallas
How many prior treatments have patients received?
0
2
3+

What questions have other patients asked about this trial?

How long is the screening process?
PatientReceived 2+ prior treatments

Why did patients apply to this trial?

I have tried several anti- depressants in the past and did not really achieve any real satisfaction for my condition.
PatientReceived 1 prior treatment
I’ve tried tried every SSRI ssnri atypical antidepressant, antipsychotic, ketamine etc nothing works on lithium now and unhappy.
PatientReceived no prior treatments
I have tried many medications, types of therapy, being active, vitamins, etc for treatment and I still suffer and I want to see if something else might work. I also would like to be apart of something that could potentially help others.
PatientReceived no prior treatments

How responsive is this trial?

Average response time
  • < 2 Days
Most responsive sites:
  1. Cerebral - New York City: < 24 hours
  2. Cerebral - Dallas: < 48 hours
Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
ALTO-300 in Depression (ALTO-300-004)
2022. "ALTO-300 in Depression (ALTO-300-004)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05157945.
~47 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top